Hoffmann-la Roche

This phase 3 trial tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without the disease worsening. Participants first receive standard induction chemo-immunotherapy, then those with stab…

This phase 2 trial tests whether prasinezumab, given as an IV infusion every 4 weeks, can slow motor decline in people with early Parkinson's disease. The study includes 586 participants who are already on stable Parkinson's medication. Researchers are measuring how long it takes…

This Phase 3 study tests whether a new drug, inavolisib, combined with fulvestrant works better than the current standard alpelisib plus fulvestrant for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The trial enrolled …

This study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Partic…

This Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…

This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…

This phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…

This Phase 3 trial tests whether the drug Afimkibart can help people with moderate-to-severe ulcerative colitis achieve remission. About 400 adults who have not responded well to other treatments will receive either Afimkibart or a placebo. The study measures remission at 12 and …

This Phase 2 trial tests a drug called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. The drug is an antibody that blocks myostatin, a protein that normally limits muscle growth, to help pres…

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This large Phase 3 study tests a new drug, giredestrant, against standard hormone therapies in about 4,170 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at preventing the cancer from returning after initial treatment. Parti…

This study tests a new drug called giredestrant in people with a type of advanced breast cancer (ER-positive, HER2-negative) that has progressed after prior treatments. About 303 participants will receive either giredestrant or another standard hormone therapy chosen by their doc…

This study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …

This study tests whether adding the experimental drug inavolisib to two standard treatments (palbociclib and fulvestrant) can slow cancer growth in people with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer. About 325 parti…

This phase 3 trial is testing whether adding the drug glofitamab to a standard chemotherapy combination (Pola-R-CHP) works better than the standard combo alone for people with untreated large B-cell lymphoma. About 1,130 participants will receive either the new combination or the…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests an experimental drug called RO7126209 (Trontinemab) in people with early to moderate Alzheimer's disease. The drug is given by IV infusion and aims to reduce amyloid plaques in the brain, a hallmark of Alzheimer's. About 241 participants will receive either the d…

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This study tests whether adding an experimental drug (RO7204239) to an existing SMA medicine (risdiplam) can help people with spinal muscular atrophy build stronger muscles and move better. The trial includes about 259 children and young adults, ages 2 to 25, who can walk. Resear…

This phase 3 trial tests whether satralizumab can prevent relapses in people with MOGAD, a rare disease where the immune system attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to see if satral…

This phase 2 trial is testing several targeted drugs in people with rare types of ovarian cancer that have come back or not gone away. The drugs are chosen based on specific biomarkers in each patient's tumor. The goal is to see if these treatments can shrink or control the cance…

This large study is testing several targeted therapies and immunotherapies for people with advanced non-small cell lung cancer. Instead of a tissue biopsy, a simple blood test is used to find specific genetic changes in the cancer. The goal is to see if matching the right drug to…

This study tests a small, refillable implant placed in the eye that delivers medication every 24 weeks, compared to standard monthly eye injections. It includes about 634 adults with diabetic macular edema, a condition that causes vision loss. The goal is to see if the implant wo…

This early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests a new drug called englumafusp alfa, which helps the immune system attack cancer cells. It is given together with either obinutuzumab or glofitamab to people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. The trial has three par…

This study tests whether a newer targeted drug, entrectinib, works better than the current standard drug, crizotinib, for people with advanced lung cancer that has a specific genetic change (ROS1). About 220 participants will take one of the two pills daily. The study focuses on …

This early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see …

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial tests an experimental oral drug called ZN-A-1041, alone or with other cancer drugs, in people with HER2-positive advanced solid tumors (including breast cancer that has spread to the brain). The study aims to find safe doses and check how the drug works in …

This phase 2 trial tests an experimental drug called tominersen in 301 people with early-stage Huntington's disease. The drug aims to lower levels of the harmful mutant protein that causes the disease. Researchers will compare tominersen against a placebo to see if it can slow do…

This Phase 3 trial is testing whether a new drug called giredestrant, combined with palbociclib, works better than the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive eit…

This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…

This study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…

This study tests an experimental drug called astegolimab against a placebo in 1290 people with COPD who have frequent flare-ups. Participants are current or former smokers. The main goal is to see if the drug reduces the number of moderate to severe COPD attacks over one year.

This study tests an experimental daily pill (RO7269162) in 256 people who either have brain plaques but no symptoms, or have mild memory problems due to Alzheimer's. Participants take the pill or a placebo for about 1.5 years, with regular check-ups to monitor safety and brain ch…

This study tests a new medicine, crovalimab, for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. It involves healthy volunteers and people with PNH to check safety and how well the drug works. The goal is to control the disease, not …

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. T…

This study tests satralizumab, a drug that calms inflammation, in 30 children aged 8 to 17 with Duchenne muscular dystrophy. The goal is to see if it improves bone density and muscle function. Participants receive injections for several months while continuing standard steroid th…

This study tests whether adding an experimental drug (RO7204239) to an existing weight-loss medication (tirzepatide) helps adults with obesity or overweight lose more weight over 48 weeks. About 285 participants without diabetes will receive either the combination or a placebo pl…

This Phase 3 study tests whether obinutuzumab, an antibody drug given by IV, can better control active lupus compared to a placebo. About 303 adults with lupus who have high disease activity and specific antibodies are taking part. All participants continue their usual lupus medi…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This study tests a gene therapy called delandistrogene moxeparvovec in 13 children under age 4 with Duchenne muscular dystrophy. The goal is to see if it is safe and can help produce a key muscle protein. The children will be followed for about 5 years.

This study tests a new drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug improves eczema symptoms by at least 75% aft…

This study tests a drug called obinutuzumab for people with lupus nephritis, a kidney disease caused by lupus. About 271 participants receive either the drug or a placebo, added to their usual treatment. The goal is to see if the drug helps achieve complete kidney response, meani…

This phase 3 trial tests crovalimab in about 50 people with PNH who have not used similar drugs before. PNH causes red blood cells to break apart, leading to fatigue, pain, and need for transfusions. Crovalimab is given as an IV infusion and then as injections under the skin to b…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests whether combining newer immunotherapy drugs with a standard targeted therapy (axitinib) can safely control advanced kidney cancer. About 199 adults with untreated, advanced clear-cell renal cell carcinoma will receive one of three drug combinations. The main goal…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a drug called cevostamab in 90 people with multiple myeloma that has returned or not responded to prior treatments, including BCMA-targeted therapies. Participants receive cevostamab by IV every 3 weeks. The goal is to see if the drug can shrink tumors and how sa…

This study tests a new once-daily pill called RO7795081 for weight loss in adults with obesity or overweight who also have weight-related health problems like high blood pressure or sleep apnea. The trial involves 352 participants and lasts 38 weeks, comparing the drug to a place…

This early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…

This phase 3 trial tests whether a refillable eye implant delivering ranibizumab can be safely used every 36 weeks instead of every 24 weeks for people with wet age-related macular degeneration. About 451 participants who have already responded to standard injections will receive…

This Phase 3 study tests whether a new combination of drugs (mosunetuzumab plus lenalidomide) works better than the current standard (rituximab plus lenalidomide) for people with follicular lymphoma that has returned after at least one prior treatment. About 478 participants will…

This study tests a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is given either as an eye injection or through a small implant placed in the eye that releases the drug over time. The trial involv…

This Phase 3 trial tests satralizumab, a drug that blocks IL-6, in 131 people with moderate-to-severe thyroid eye disease. The main goal is to see if it reduces eye bulging by at least 2 mm after 24 weeks. Participants receive either satralizumab or placebo injections, and resear…

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This study compares a targeted drug (alectinib) taken as a pill for 2 years against standard chemotherapy after surgery for a specific type of lung cancer (ALK-positive). About 257 adults with stage IB to IIIA lung cancer that was fully removed will participate. The goal is to se…

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …

This study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…

This study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…

This study tests a new drug called glofitamab, given alone or with obinutuzumab, in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior treatments. The trial has three parts to find the best dose and check safety and effectiveness. About 940 par…

This study tests whether faricimab, an already-approved eye injection, can be given every 24 weeks (about twice a year) to people newly diagnosed with wet age-related macular degeneration (AMD). The trial involves 274 participants and will measure how well vision is maintained ov…

This phase 3 study tests whether the immune-boosting drug atezolizumab can delay or prevent lung cancer from coming back in patients who have already had surgery and chemotherapy. About 1,280 people with stage IB to IIIA non-small cell lung cancer are taking part. Half receive at…

This phase 3 trial compares crovalimab, a new injectable drug, to eculizumab in about 190 people with paroxysmal nocturnal hemoglobinuria (PNH) who are already on complement inhibitors. The study aims to see if crovalimab is as safe and effective, with a focus on side effects and…

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…

This study tests a stem cell therapy called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy). Researchers inject retinal pigment epithelium cells derived from human embryonic stem cells into the eye to see if they can safely replace damag…

This study tests whether crovalimab works as well as eculizumab for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 210 adults who have not had prior complement inhibitor therapy will receive either drug. The main goals are to see if crovalimab…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay the cancer from getting worse. About 342 adults with liver cancer who are not cand…

This Phase IV study is testing emicizumab (Hemlibra) in 136 people aged 13 to 70 with moderate or severe hemophilia A who do not have inhibitors. The goal is to see if this drug, given as a shot under the skin, can improve joint health, increase physical activity, and enhance ove…

This Phase 2 trial tests two new immunotherapy drugs, tobemstomig alone or with tiragolumab, against the standard drug atezolizumab. It includes 204 people with advanced bladder cancer who cannot have platinum chemotherapy. The main goal is to check safety and side effects.

This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate tumors in people with locally advanced rectal cancer. About 58 participants will receive either the drug combination or atezolizumab alone befor…

This study tests a new medicine called crovalimab for people with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots and kidney damage. The trial includes 83 adults and teens who receive the drug to see if it can control the disease and impr…

This study tests whether adding tiragolumab to atezolizumab can help control esophageal cancer that hasn't grown after standard chemoradiotherapy. About 760 adults with inoperable esophageal squamous cell carcinoma will receive either the drug combination, atezolizumab alone, or …

This study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with advanced HER2-positive, estrogen receptor-positive breast cancer live longer without their cancer getting worse. About 922 participants who have not had prior treatment for a…

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring from MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body processes it. Researchers will also check if it can reduce liver stiffnes…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…

This study is testing a medicine called emicizumab (Hemlibra) in babies from birth to 12 months old with severe hemophilia A. The goal is to see if a weekly or biweekly shot under the skin can prevent bleeding episodes and protect joints. About 55 infants will receive the drug fo…

This study offers continued treatment with atezolizumab (Tecentriq) for cancer patients who were already receiving it in a prior Roche-sponsored trial. It includes 382 participants and aims to provide uninterrupted therapy while monitoring long-term safety and survival. The study…

This phase II trial is testing an oral drug called giredestrant in 30 people with grade 1 endometrial cancer. The goal is to see if the drug can shrink or control the cancer over 6 months. Participants take one pill daily for up to 24 cycles, and doctors monitor tumor changes and…

This early-stage trial tests whether a drug called RO7204239 can improve how the body uses insulin and affects muscle composition in 30 adults with type 2 diabetes who are overweight or obese. Participants will receive either the drug or a placebo, and researchers will measure ch…

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…

This Phase 2 study tests a new once-daily pill called RO7795081 for people with type 2 diabetes. About 240 adults whose diabetes is not well controlled will take the drug, a placebo, or an existing medication (semaglutide) for 30 weeks. The main goal is to see if RO7795081 lowers…

This study tests the drug risdiplam (Evrysdi) in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment can help them reach motor milestones like sitting without support. The trial involve…

This study tests a drug called obinutuzumab against a standard treatment (tacrolimus) in 142 adults with primary membranous nephropathy, a kidney disease that lets protein leak into urine. The goal is to see if obinutuzumab can bring about complete remission (no protein in urine)…

This phase 3 trial tests whether adding the immunotherapy glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than the usual rituximab-chemotherapy combo for people with diffuse large B-cell lymphoma that has come back or not responded to prior treatmen…

This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This phase III trial is testing the immunotherapy drug atezolizumab (Tecentriq) in 60 people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. Participants receive the drug every three weeks. The study aims to see if it helps the…

This Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…

This phase 3 trial tests crovalimab in 41 children with atypical hemolytic uremic syndrome (aHUS), a rare disease that causes blood clots and kidney damage. The drug is given first through a vein, then as a shot under the skin every four weeks. The goal is to see if it can stop d…

This study tests whether the immunotherapy drug atezolizumab can delay or prevent bladder cancer from coming back after surgery. It includes 761 high-risk patients whose blood tests showed cancer DNA after bladder removal. Participants receive either atezolizumab or a placebo to …

This study tests an experimental drug called prasinezumab in 316 people with early Parkinson's disease. The drug is an antibody designed to target and remove clumps of a protein linked to Parkinson's. Participants receive either the drug or a placebo for 52 weeks, with an option …

This Phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (Kadcyla) can prevent breast cancer from returning in people with high-risk HER2-positive breast cancer. About 1,188 participants who still had cancer af…

This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune disease that increases clot risk. The trial was withdrawn before enrolling any participants, so no re…

This phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…

This Phase 3 study tests whether adding tiragolumab (an experimental immunotherapy) to the standard combination of atezolizumab plus chemotherapy can help people with untreated, widespread small cell lung cancer live longer without their disease worsening. About 123 participants …

This study aimed to see if adding the targeted drug inavolisib to standard chemotherapy and bevacizumab could help people with a specific genetic form of advanced colorectal cancer (PIK3CA-mutated). It was designed for adults who had not yet received treatment for metastatic dise…

This study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…

This phase 3 trial is testing whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab helps people with advanced liver cancer that cannot be surgically removed. About 687 participants will receive either the three-drug combo or the two-drug combo pl…

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …

This study tests a drug called obinutuzumab against a standard treatment (MMF) in children and young adults with a kidney condition that causes frequent relapses. The goal is to see if obinutuzumab can keep the disease in remission longer and reduce the need for steroids. About 8…

This study will follow 3,000 people with COPD who have frequent flare-ups to see how the disease changes over time and what treatments they receive. Researchers will collect information from medical records and surveys to understand treatment patterns, quality of life, and caregi…

This study observes 44 people with type 3 von Willebrand disease, a rare bleeding disorder, who are already on standard preventive treatment. Researchers will track how often bleeding episodes occur and how the condition affects quality of life over at least 24 weeks. No new drug…

This study is collecting long-term, real-world data from about 6,000 adults being treated with Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to unders…

This study follows 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will collect data from routine clinic visits over one year to see how well the drug works and ho…

This study tracks 378 people with moderate to severe dry eye disease and healthy volunteers to see how signs, symptoms, and biomarkers change after treatment with either Vevye or Xiidra eye drops. The goal is to find better ways to measure the disease and its response to therapy.…

This study is watching nearly 3,000 people newly diagnosed with breast cancer in Latin America. It does not test a new treatment but instead collects information on how the cancer is diagnosed, what treatments are used, and how patients do over time. The goal is to better underst…

This study follows about 800 people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib as part of their routine care. Researchers want to see how long the cancer stays under control and how patients are managed in real-world clinics, not just …

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments they receive, how lo…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …